Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).

Eur J Cancer · 2025 · PMC13075548 · PMID 40803104

Europe PMC DOI

hedged sentence

0.2600

closest p · 5.2× alpha

0.2600

boldest claim

The sentences

did not reach statistical significancep = 0.26not close (p > 0.1)

However, median OS in the same group was 41.0 months for bev vs 28.5 months for cet, although this difference did not reach statistical significance (adjusted HR [95 % CI] = 0.78 [0.51, 1.20], p = 0.26).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.